Metformin use associated with decreased risk of colorectal cancer
the ONA take:
According to a new study published in the journal Cancer, researchers from the University of Chicago in Chicago, Illinois, have found that metformin use is associated with a decreased risk of developing colorectal cancer.
Metformin is typically the first-line oral treatment for patients with type 2 diabetes mellitus. For the study, researchers sought to examine the effects of metformin on colorectal cancer incidence in a U.S. population.
Using MarketScan databases, researchers identified patients with diabetes and colorectal cancer with each case being matched with up to two controls. The mean age of participants was 57 years for cases and 55 years for controls.
Results showed that metformin use was associated with a 15% risk reduction for the development of colorectal cancer, which was reduced to 12% after adjusting for health care use.
Researchers also found that there was no significant association between metformin dose, duration of treatment, or total exposure and risk of colorectal cancer.
Metformin use is associated with a decreased risk of developing colorectal cancer.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|